Analysten nachrichten

Pharnext Executes a Financing Agreement with Néovacs for EUR 20.7 million Net to Further Develop PXT3003 for Charcot-Marie-Tooth Disease Type 1A

External page is loading, the page should display in a few seconds..

    Follow @AnalystenNews on Twitter!